Next Article in Journal
Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
Next Article in Special Issue
Microsatellite Instability in Colorectal Cancer Liquid Biopsy—Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker
Previous Article in Journal
Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice
Previous Article in Special Issue
Baseline and Kinetic Circulating Tumor Cell Counts Are Prognostic Factors in a Prospective Study of Metastatic Colorectal Cancer
Article

RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer

1
Analysis of Circulating Tumor Cells Lab, Department of Chemistry, University of Athens, 15771 Athens, Greece
2
Medical Oncology Unit, “Elena Venizelou” Hospital, 11521 Athens, Greece
3
Metropolitan General Hospital, 15562 Athens, Greece
*
Author to whom correspondence should be addressed.
Academic Editor: Rita Zamarchi
Diagnostics 2021, 11(3), 513; https://doi.org/10.3390/diagnostics11030513
Received: 17 February 2021 / Revised: 8 March 2021 / Accepted: 12 March 2021 / Published: 14 March 2021
In metastatic breast cancer (MBC) the molecular characterization of circulating tumor cells (CTCs) provides a unique tool to understand metastasis-biology and therapy-resistance. We evaluated the prognostic significance of gene expression in EpCAM(+) CTCs in 46 MBC patients based on a long follow-up. We selected a panel consisting of stem cell markers (CD24, CD44, ALDH1), the mesenchymal marker TWIST1, receptors (ESR1, PGR, HER2, EGFR) and the epithelial marker CK-19. Singleplex RT-qPCR was used for TWIST1 and CK-19 and multiplex RT-qPCR for stem cell markers and receptors. A group of 19 healthy donors (HD) was used as control. Univariate (p = 0.001) and multivariate analysis (p = 0.002) revealed the prognostic value of combined gene expression of CK-19(+), CD44high/CD24low, ALDH1high/CD24low and HER2 over-expression for overall survival (OS). The Kaplan–Meier estimates of OS were significantly different in patients positive for CK-19 (p = 0.028), CD44high/CD24low (p = 0.002), ALDH1high/CD24low (p = 0.007) and HER2-positive (p = 0.022). Our results indicate that combined gene expression analysis in EpCAM(+) CTCs provides prognostic information in MBC. View Full-Text
Keywords: liquid biopsy; circulating tumor cells; gene expression; metastatic breast cancer; multiplex RT-qPCR; prognostic marker liquid biopsy; circulating tumor cells; gene expression; metastatic breast cancer; multiplex RT-qPCR; prognostic marker
Show Figures

Figure 1

MDPI and ACS Style

Strati, A.; Nikolaou, M.; Georgoulias, V.; Lianidou, E.S. RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer. Diagnostics 2021, 11, 513. https://doi.org/10.3390/diagnostics11030513

AMA Style

Strati A, Nikolaou M, Georgoulias V, Lianidou ES. RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer. Diagnostics. 2021; 11(3):513. https://doi.org/10.3390/diagnostics11030513

Chicago/Turabian Style

Strati, Areti, Michail Nikolaou, Vassilis Georgoulias, and Evi S. Lianidou. 2021. "RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer" Diagnostics 11, no. 3: 513. https://doi.org/10.3390/diagnostics11030513

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop